Small heat-shock protein HSPB1 mutants stabilize microtubules in Charcot-Marie-Tooth neuropathy by Almeida-Souza, Leonardo et al.
Neurobiology of Disease
Small Heat-Shock Protein HSPB1Mutants Stabilize
Microtubules in Charcot-Marie-Tooth Neuropathy
Leonardo Almeida-Souza,1 Bob Asselbergh,1 Constantin d’Ydewalle,2 Kristof Moonens,3 Sofie Goethals,1
Vicky deWinter,1 Abdelkrim Azmi,4 Joy Irobi,1 Jean-Pierre Timmermans,5 Kris Gevaert,6 Han Remaut,3
Ludo Van Den Bosch,2 Vincent Timmerman,1 and Sophie Janssens1,7
1Peripheral Neuropathy Group, Department of Molecular Genetics, VIB and University of Antwerp, Antwerp 2610, Belgium, 2Laboratory for Neurobiology,
Vesalius Research Center, VIB and University of Leuven, Leuven 3000, Belgium, 3Laboratory for Structural and Molecular Microbiology, VIB Department of
Cellular and Molecular Interactions, Vrije Universiteit Brussel, Brussels 1050, Belgium, 4Centre for Proteome Analysis and Mass Spectrometry, Department
of Biology, and 5Laboratory of Cell Biology and Histology, Department of Veterinary Sciences, University of Antwerp, Antwerp 2020, Belgium, 6Department
of Medical Protein Research, VIB and Department of Biochemistry, Ghent University, Ghent 9000, Belgium, and 7GROUP-ID Consortium, Laboratory for
Immunoregulation and Mucosal Immunology, Department of Pulmonary Medicine, University Hospital of Ghent, Ghent 9000, Belgium
Mutations in the small heat shock protein HSPB1 (HSP27) are causative for Charcot-Marie-Tooth (CMT) neuropathy. We previously
showed that a subset of thesemutations displays higher chaperone activity and enhanced affinity to client proteins.Wehypothesized that
this excessive binding propertymight cause theHSPB1mutant proteins to disturb the function of proteins essential for themaintenance
or survival of peripheral neurons. In the present work, we explored this hypothesis further and compared the protein complexes formed
bywild-type andmutantHSPB1.Tubulin cameout as themost strikingdifferential interactingprotein,withhyperactivemutants binding
more strongly to both tubulin and microtubules. This anomalous binding leads to a stabilization of the microtubule network in a
microtubule-associated protein-like manner as reflected by resistance to cold depolymerization, faster network recovery after nocoda-
zole treatment, and decreased rescue and catastrophe rates of individual microtubules. In a transgenic mouse model for mutant HSPB1
that recapitulates all features of CMT,we could confirm the enhanced interactionofmutantHSPB1with tubulin. Increased stability of the
microtubule network was also clear in neurons isolated from thesemice. Since neuronal cells are particularly vulnerable to disturbances
in microtubule dynamics, this mechanismmight explain the neuron-specific CMT phenotype caused by HSPB1 mutations.
Introduction
Charcot-Marie-Tooth (CMT) disease represents a large group of
genetically and clinically heterogeneous disorders affecting the
peripheral nervous system. Clinically, CMT disease is character-
ized by a length-dependent degeneration of peripheral nerves
resulting in weakness and wasting of distal muscles in lower
limbs, feet and hands. So far, mutations in40 genes have been
linked to CMT neuropathy and related disorders (Barisic et al.,
2008). In 2004, we found that dominant missense mutations in
the small heat shock protein HSPB1 (also known as HSP27) were
linked toCharcot-Marie-Tooth type 2F and distal hereditarymo-
tor neuropathy (HMN) (Evgrafov et al., 2004).
Small heat shock proteins (sHSPs) are ubiquitously expressed
molecular chaperones characterized by the presence of a con-
served -crystallin domain. In contrast to heat shock proteins
with an ATPase domain (e.g., HSP70), sHSPs do not have the
intrinsic capacity to actively refold denatured proteins. However,
they are capable of binding unfolded substrates and keeping them
in a folding-competent state until these are cleared out by the
ATP-dependent heat shock proteins (Haslbeck et al., 2005).
HSPB1 is one of the most studied sHSPs due to its role in several
human disorders including cancer, Alzheimer’s disease, and
heart disease (Sun and Macrae, 2005).
In a previous study, we addressed how mutations in HSPB1
might cause a peripheral neuropathy and characterized the bio-
chemical consequences of CMT-causing mutations on the basic
properties of this protein. In contrast to most other chaper-
onopathies, mutations in the -crystallin domain localized close
to the HSPB1 dimer interface (R127W, S135F, and R136W) lead
to an increase, rather than a loss, of chaperone activity. This
hyperactivation was corroborated by an increased affinity of the
mutants for their client proteins. Two other mutations, one situ-
ated at the border of the -crystallin domain (T151I) and one at
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the C terminus of the protein (P182L) did not show this hyper-
activation (Almeida-Souza et al., 2010).Wehypothesized that the
excessive binding properties of the hyperactive mutants might
disturb the function of HSPB1 client proteins that are essential
for the survival of peripheral neurons.
To identify aberrant interactions caused by these hyperactive
mutations, we compared the protein complexes formed by wild-
type and mutant HSPB1 by tandem affinity purification. We
found that hyperactive mutants exhibit enhanced interaction
with tubulin and microtubules (MTs), which leads to a stabiliza-
tion of the microtubule network. Importantly, the increased in-
teraction of mutant HSPB1 with tubulin and the enhanced
stability of the microtubule network were also obvious in neu-
rons isolated from a mouse model that expresses mutant HSPB1
and recapitulates the typical CMT symptoms.
Materials andMethods
Stable cell line generation, constructs, and recombinant protein production.
Stable HEK293Flp-in cell lines were generated as described previ-
ously (Almeida-Souza et al., 2010) using constructs carrying HSPB1
C-terminally fused to a tandem affinity purification (TAP) tag composed
of Flag, TEV, cleavage site, and Protein A (Tsai and Carstens, 2006).
StableHeLa cell lines were produced by lentiviral transduction according
to themethod described in Salmon and Trono (2006) and the constructs
described previously (Almeida-Souza et al., 2010). TUBB3-GFP and
EB1-GFP constructs were generated using Gateway recombination (In-
vitrogen). For recombinant protein production, the ORF from HSPB1
was amplified by PCR and cloned by topoisomerase cloning into the
vector pCRT7-NT-TOPO (Invitrogen). Protein expression was induced
in BL21 DE3 cells, and proteins were purified on a Ni-NTA column.
Dorsal root ganglion neuronal cultures. Dorsal root ganglion (DRG)
neurons, isolated from 3-month-old CO2-killed mice, were dissociated
by incubation at 37°Cwith 0.5% collagenase for 45min and 1.5% trypsin
for 30 min. Cell suspensions were washed with DRGprep medium
[DMEMmedium supplemented with bovine serum (10%), nonessential
amino acids (1%), L-glutamine (1%), and NaHCO3 (0.15%)], and cen-
trifuged at 800  g for 5 min. The pellet was resuspended in DRGprep
and incubated for 50 min at 37°C and 7% CO2 on a bovine serum cush-
ion. Next, cell suspension was centrifuged for 5 min at 800 g, and the
pellet was resuspended in DRG medium [DMEM:F12 medium supple-
mented with L-Glutamax (4 mM), bovine serum (10%), nonessential
amino acids (1%), penicillin/streptomycin (50 U/ml), NGF (10 ng/ml;
Millipore), and NaHCO3 (0.045%)]. DRG neurons were seeded at a
density of 100 cells/well coated with poly-L-ornithine and laminin
(Sigma), and incubated at 37°C and 7% CO2.
Tandem affinity purification and mass spectrometry. TAPs for mass
spectrometric protein identification were done by upscaling the protocol
described before (Almeida-Souza et al., 2010). HEK293 stable cell lines
were grown in 10 150 cm2 dishes, harvested with a cell scraper, and
washed two times with PBS. Cell pellets were lysed in 10 ml of TAP lysis
buffer (50 mM Tris-HCl, pH 8.0, 10% glycerol, 1% NP40, 150 mM NaCl,
5 mM NaF, 5 M ZnCl2, 1 mM Na3VO4, 10 mM EGTA, and Protease
inhibitor cocktail (Roche). Equal amounts of cytosolic lysates from each
stable cell line were incubated with 200 l of IgG beads (GE Healthcare)
for 4 h at 4°Cwith constant agitation. Beadswerewashed three timeswith
washing buffer (20 mM Tris-HCl, pH 7.5, 5% glycerol, 0.1% NP40, and
150 mM NaCl) and three additional times with TEV protease cleavage
buffer (10 mM Tris-HCl, pH 8, 150 mM NaCl, 0.1% NP40, and 0.5 mM
EDTA). The washed IgG beads were then incubated overnight at 4°C and
with constant agitation with 100 U of AcTEV protease (Invitrogen) in
500l of TEV protease cleavage buffer. After TEV cleavage, the superna-
tants containing the eluted complexes were incubated with 200 l of
anti-Flag beads (Sigma) for 4 h at 4°C with constant agitation. After
incubation, beads were washed gently three times with washing buffer.
Final elution was done by incubation of the Flag beads for 30 min at 4°C
with 250 ng/l of the 3xFlag peptide. Final eluates were run on NuPAGE
gels (Invitrogen) and Coomassie stained. Bands of interest were excised
and digested with sequencing grade-modified trypsin according to the
manufacturer’s instructions (Promega). The resulting protein digests
were analyzed by liquid chromatography-tandem mass spectrometry
(LC-MS/MS) using a Bruker HCT Esquire ion trap mass spectrometer,
and protein identification was done using the Mascot algorithm (95%
confidence level).
Immunoprecipitation from cells and mouse sciatic nerve. Immunopre-
cipitations fromHEK293 stable cell lines were performed using the same
protocol as described for the TAP experiments until the first elution step
after TEV protease cleavage and using only 5 mg of cell lysates. For the
immunoprecipitations from mouse sciatic nerves, tissue homogenates
were prepared using the extraction reagent from the ProFoundMamma-
lian HA-tag IP/coIP kit (Thermo Fisher Scientific) with Lysing Matrix A
(MP Biomedicals). Immunoprecipitation of the HA-tagged HSPB1 was
performed according to manufacturer’s instructions.
Ice-induced microtubule depolymerization assay. HEK293Flp-in cells
were seeded in 6-well plates in triplicate. Forty-eight hours after seeding,
plates were placed on ice for the described time and subsequently lysed
with MT stabilization buffer (20 mM Tris, pH 6.8, 2 mM EGTA, 1 mM
MgCl2, 0,5%NP-40, 140mMNaCl, and 4.7M taxol) (Bhattacharya and
Cabral, 2004). After lysis, cell extracts were centrifuged at 20,000 g for
10min to separate the soluble from polymerized tubulin. Ratios between
polymerized and unpolymerized tubulin were calculated by densitomet-
ric measurement of Western blot bands using ImageJ.
Microtubule network recovery and nocodazole washout experiments.
HeLa cells were seeded in 24-well plates containing coverslips and treated
48 h later with 10 m nocodazole for 6 h. After treatment, media was
changed and cells were allowed to recover for different periods. After
recovery, soluble tubulin was washed away by detergent extraction
(BRB80 containing 0.5% Triton X-100 for 30 s). Cells were then fixed
with 3% paraformaldehyde (PFA) and stained for -tubulin (ab7291,
Abcam). Confocal image stacks from several cells were taken with a Zeiss
LSM700 confocalmicroscope equippedwith a 63 1.4NAobjectivewith
identical acquisition parameters. Total MT fluorescence intensity was
determined by measuring average pixel intensities on maximum inten-
sity projections for individual cells by use of ImageJ.
Neuronal microtubule depolymerization and repolymerization assay.
Assays were performed on DRG neurons at 2 d in vitro. At various time
points during or after nocodazole (20M) treatment, neurons were fixed
with 4% PFA after being subjected to detergent extraction and were
subsequently stained for -tubulin (ab7291, Abcam). Images were ac-
quired on a Zeiss Imager M1 fluorescence microscope using a 20 0.45
NA objective.MT network length was determined for the longest neurite
per neuron using the Single Neurite Tracer Plugin for ImageJ. MT net-
work length was normalized to the initial size before treatment.
HSPB1 and tubulin interaction measurements in cells. Cos-1 cells were
transiently transfected with HSPB1-V5 and TUBB3-GFP constructs,
fixed with 3% PFA 48 h after transfection, and processed for immuno-
fluorescence using amousemonoclonal anti-HSPB1 antibody (SPA-803,
Stressgen). Cos-1 cells were chosen for the in vivo colocalization experi-
ments due to their low endogenous HSPB1 levels, high transfection effi-
ciency, and large flat cytoplasmic extensions. Two-channel sequentially
scanned images were acquired with a Zeiss LSM700 confocal microscope
with 63 1.4 NA objective. Pearson’s correlation coefficient was calcu-
lated for 50 cytoplasmic regions (200 200 pixels) from10 different cells
using the JACoP ImageJ plugin (Bolte and Cordelie`res, 2006). Fluores-
cence intensity profile graphs were generated by using the plot profile
feature from ImageJ froma randomly traced line in the cortical regions of
cells. Fluorescence valueswere normalized by setting the highest value for
each channel as 1.
Microtubule cosedimentation assay. Cell extracts from HEK293Flp-in
cells were diluted 1:1 in BRB80 (80 mM PIPES, 1 mM MgCl2, and 1 mM
EDTA); supplemented with 1mMGTP, 2mMATP, and 25M taxol; and
incubated at 37°C for 30min. After incubation, reactions were layered on
a 40%glycerol cushion and centrifuged at 100,000 g for 30min at 37°C.
Supernatant was separated into another tube, and the pellet was washed
with BRB80 and resuspended in the same volume as the supernatant. The
experiment was repeated three times, and the ratio between soluble and
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MT-bound HSPB1 was calculated by densito-
metricmeasurement ofWestern blot bands us-
ing ImageJ.
Microtubule dynamics measurements. HeLa
cells stably expressing different HSPB1 iso-
forms were cultivated in 35 mm glass-bottom
dishes and transfected with the TUBB3-GFP or
EB1-GFP constructs using lipofectamine LTX
(Invitrogen). Cells were imaged 72 h after
transfection for 2 min at 3 s/frame for TUBB3-
GFP-transfected cells and at 2 s/frame for EB1-
GFP-transfected cells on a Zeiss Axiovert 200
microscope with a microlens-enhanced dual
spinning disc confocal system (UltraVIEW
ERS; PerkinElmer), equipped with a 60 1.4
NA objective. During imaging, cells were
maintained at 37°C and 5% CO2. Individual
TUBB3-GFP MTs were tracked manually us-
ing theManual Tracking plugin of ImageJ, and
dynamicity parameters were extracted from
data by a custom-made Perl script. The MTs
were considered static if theymoved0.3m/
frame. The speed and distance traveled by EB1-
GFP comets were calculated by automatic
tracking using the Particle Tracker plugin of
ImageJ.
Scratch-inducedmigrationassay.HEK293Flp-in
cells were grown to confluence on 24-well
plates and treated for 30 min with 5 M cell
tracker (Invitrogen) before being scratched
with a pipette tip. Cells were imaged with a
10 objective by phase contrast and fluores-
cence video microscopy using a Zeiss Axiovert
200 microscope equipped with an incubation
chamber at 37°C and 5% CO2. The migration
history was plotted as the area covered by cells
every 2 h, subtracted from the area occupied by
the cells at the time 0 of the experiment.
In vitro microtubule polymerization assays.
Microtubule assembly wasmonitored byDAPI
fluorescence according to the protocol de-
scribed previously (Barron et al., 2003). Po-
lymerization was performed using 10 M microtubule-associated
protein (MAP)-rich tubulin (Cytoskeleton Inc) in BRB80 buffer, 1 mM
GTP, 10 M DAPI, and recombinant HSPB1 at 5 M when stated. The
fluorescence of MT-bound DAPI was monitored with a BioTek plate
reader every 30 s with the temperature set to 37°C and excitation/
emission wavelengths set to 360/450 nm.
Binding assay by surface plasmon resonance. Surface plasmon resonance
(SPR) experiments were performed using a Biacore 3000 instrument.
The surface of a CM5 sensor chip was activated with a 1:1mixture of 0.1 M
N-hydroxysuccinimide and 0.4 M 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride. After activation of the surface, tubulin
(50 g/ml) in 10 mM sodium acetate, pH 4, was injected to flow cell 2
(FC2) to be immobilized on the sensor surface via primary amine groups.
Residual active ester groups were blocked with 1 M ethanolamine-HCl,
pH 8.5. As a control, FC1 was activated and deactivated as described for
FC2. HSPB1WT and HSPB1S135F was flowed over the chip surface with
concentrations ranging from 40 M to 19.5 nM and 25.7 M to 12.6 nM,
respectively, in degassedHBS buffer (10mMHEPES, 150mMNaCl, 1mM
EDTA, 0.005% Tween20, pH 7.4) at a flow rate of 20 l/min at 25°C
during 2min. Dissociation was done in HBS buffer over 30min until the
baseline level was reached. Data were evaluated using the software BIAe-
val (Biacore AB). The subtracted (FC2 FC1) equilibrium signals were
plotted versusHSPB1 concentrations, and a steady-state affinity model
was fitted to the data, from which the dissociation constant KD was
obtained.
Statistical analysis. For all experiments, statistical significance for the
different measurements was tested using a two-tailed t test, with the
exception of the individual MT dynamics measurements, where statisti-
cal difference was evaluated by an ANOVA followed by a Bonferroni
multiple test correction.
Results
CMT neuropathy-causing HSPB1mutants show enhanced
binding to tubulin and microtubules
To address how hyperactive HSPB1 mutations may cause CMT
neuropathy, we compared the protein complexes formed by
HSPB1WT and mutant isoforms. Parallel tandem affinity purifi-
cations from cells expressing equal levels of WT or mutant
HSPB1 were performed, and interacting complexes were loaded
on gel. A band running at50 kDa was clearly more prominent
in the lanes containing the-crystallinHSPB1mutants (Fig. 1A).
Mass spectrometric identification revealed that this band corre-
sponded to - and -tubulin. Immunoprecipitation with all the
CMT disease-causing mutations previously identified in our
group (Evgrafov et al., 2004) revealed that only the hyperactive
HSPB1 mutations R127W, S135F, and R136W (Almeida-Souza
et al., 2010) showed enhanced interaction to tubulin, while
HSPB1T151I and HSPB1P182L showed a similar interaction com-
pared with HSPB1WT (Fig. 1B).
Microtubules are cold-sensitive structures that rapidly depo-
lymerize into tubulinmonomers when placed on ice (Melki et al.,
1989). Because the immunoprecipitations were performed on ice
Figure 1. Hyperactive HSPB1 mutants bind to tubulin and microtubules. A, Coomassie staining of the final eluates from TAPs
fromHEK293Flp-in cells expressing TAP-tagged HSPB1-WT, R127W, and R136W. The prominent50 kDa bandwas identified by
mass spectrometry as- and-tubulin. B, Immunoprecipitations from HEK293Flp-in cells confirmed that the three hyperactive
HSPB1 mutants (R127W, S135F, and R136W) displayed enhanced binding to tubulin. HSPB1 was detected using anti-flag anti-
body. Differences in HSPB1 size between input and the IP fractions are due to the removal of the Protein A tag during the elution
step by TEV cleavage. C, Cosedimentation assay performed to evaluateHSPB1binding toMTs. Cell extracts fromHEK293Flp-in cells
expressing different HSPB1 isoforms were supplemented or not with GTP and taxol, and incubated at 37°C to allow MT polymer-
ization. MTs were then separated from tubulin by ultracentrifugation, and the amount of HSPB1 bound to MTs (visualized by
anti-FlagWestern blot) was determined by calculating the ratio between the amount of HSPB1 in theMT and the total amount of
HSPB1 from the reactions supplemented with taxol (Graph, n 3 independent experiments). Vertical thick black lines shown in
Western blots correspond to divisions between gels. Data are presented as mean SEM. M, MT-containing fraction; S, soluble
fraction. *p 0.05; **p 0.01.
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to prevent protein degradation, we de-
cided to check whether the hyperactive
HSPB1 mutants also bind to MTs. Tubu-
lin from cellular extracts obtained from
cells expressing different HSPB1 isoforms
were polymerized and fractionated into
soluble proteins and MTs by ultracentrif-
ugation. Binding of HSPB1 to MTs was
measured by calculating the ratio be-
tween the amount of HSPB1 protein in
the MT-containing fraction and the total
amount ofHSPB1.As shown in Figure 1C,
all HSPB1 isoforms bind to MTs with the
hyperactive mutants displaying higher af-
finity to MTs compared to the HSPB1WT
protein.
To visualize the binding of HSPB1 to
MTs inside the cell, we transfected Cos-1
cells with constructs harboring V5-tagged
HSPB1WT or HSPB1S135F together with
a GFP-fused tubulin III construct
(TUBB3-GFP). As shown in Figure 2A,
HSPB1WT and HSPB1S135F showed a sim-
ilar overall distribution with a merely
cytoplasmic distribution. However, at
higher magnification, it was clear that
HSPB1S135F preferentially localized to MT-
containing regions, while the HSPB1WT
presented a more diffuse staining (Fig. 2B).
Fluorescence intensity line plots and colo-
calization calculation with the Pearson’s
correlation coefficient confirmed these
trends (Fig. 2C,D). Overall, the enhanced
binding of hyperactive mutants to MTs did
not cause any obvious change in themicro-
tubule network (Fig. 2A).
The microtubule cytoskeleton is a
structure that is especially important for
neurons, as evidenced by the fact that dis-
turbances in MT dynamics are linked to
several neurodegenerative diseases (Evans
et al., 2005; Bunker et al., 2006; Gillardon,
2009; Tanabe and Takei, 2009; Cartelli et
al., 2010; Tischfield et al., 2010). For this
reason, we decided to explore the func-
tional significance of this increased inter-
action further.
CMT neuropathy-causing HSPB1
mutants stabilize the microtubule
network
Microtubules are dynamic structures that
are regulated by a series of proteins (Baas
et al., 2005). Among these regulators,
MAPs from the MAP1 family stabilize
MTs by binding along their length (Hal-
pain and Dehmelt, 2006). To check
whether the excessive binding properties
of the hyperactive HSPB1 mutants might
turn this protein into a MAP-like mole-
cule and as such affect MT dynamics, we
started by evaluating the effects of these
mutations on depolymerization and re-
Figure 2. Colocalization ofmutant HSPB1 andmicrotubules in cells.A, Overview image from Cos-1 cells transiently transfected
with constructs harboring GFP-TUBB3 and V5-tagged HSPB1-WT or the HSPB1–S135F and stained for HSPB1. Scale bar, 5m.B,
Representative pictures for the staining with anti-HSPB1 antibody showing preferential localization of the HSPB1–S135Fmutant
to MT regions (bottom) in contrast to the overall distribution of the HSPB1-WT (top). Scale bar, 2m. C, Normalized fluorescence
intensity profiles for the white arrows traced in the merged pictures. The graphs for the HSPB1S135F mutant clearly show the
correspondence between fluorescence peaks and valleys of HSPB1 andMT, while this correspondence is less clear for HSPB1WT.D,
Pearson’s correlation coefficient between HSPB1 staining and TUBB3-GFP was calculated for 50 independent areas from 10
different cells. Data are presented as mean SEM. *p 0.05.
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polymerization of the MT network. First, we performed a
cold-induced MT depolymerization assay. Expression of hy-
peractive HSPB1 mutants rendered cells more resistant to
cold-induced MT depolymerization, which was particularly
evident at 12 min post-treatment (Fig. 3A,B). We next tested
the repolymerization capacity of the MT network by treating
cells with nocodazole and measuring the recovery of the MT
network after nocodazole washout. In accordance with the
previous result, expression of hyperactive HSPB1 mutants re-
sulted in a faster recovery of the MT network when measured
30 min after nocodazole washout (Fig. 3C). In steady-state
conditions, we never observed any obvious difference in fluo-
rescence intensity between different genotypes (data not
shown).
As an additional readout of MT network stability, we used a
scratch-induced migration assay to assess the migration capacity
of these cells. Cell migration is a process critically dependent on
Figure 3. Hyperactive HSPB1 mutants stabilize microtubules. A, B, Cold-induced MT depolymerization assay. HEK293Flp-in cells expressing different HSPB1 isoforms and EGFP as a negative
control were placed on ice for different periods of time and separated into tubulin (T) and MT (M) fractions. The ratio of polymerized tubulin was calculated by dividing the tubulin signal intensity
from M and T fractions. A, Graph showing the ratio of polymerized tubulin at different time points. B, Western blot showing tubulin and MT fractions at the zero and 12 min time points, and
quantification of the ratio M/T (n 3). C, MT network recovery experiment after nocodazole washout. HeLa cells stably expressing different HSPB1 isoforms were treated with 10M nocodazole
for 6 h; allowed to recover for 0, 10, and 30min; treatedwith detergent to remove soluble tubulin; and stained for tubulin.MT network recoverywasmeasured as total fluorescence per cell (n 58,
50, and 48 for WT; 53, 48, and 70 for R127W; and 53, 73, and 77 for S135F). Data points for HSPB1–R127W and HSPB1–S135F are statistically different from HSPB1-WT at 30 min (p 0.01). D,
Scratch-inducedmigration assay. HEK293Flp-in cells expressing different HSPB1 isoformswere grown until confluence and scratchedwith a pipette tip. Cells were imaged overnight, andmigration
wasmeasured as the areamigrated by cells every 2 h (n 12, 14, 20, and 14 for WT, R127W, S135F, and T151I, respectively). Scale bar, 80m. Data points for HSPB1–R127W and HSPB1–S135F
are statistically different from HSPB1-WT and HSPB1–T151I at 6, 8, 10, and 12 h (p 0.01). Data are presented as mean SEM. E, Tubulin acetylation levels in HEK293Flp-in cells expressing
different HSPB1 isoforms.
Table 1. Hyperactive HSPB1mutants disturbmicrotubule dynamics
HSPB1WT
(n 86 MTs)
HSPB1R127W
(n 103 MTs)
HSPB1S135F
(n 104 MTs)
Growth (%) 0.165 0.118 0.057 0.067** 0.067 0.075**
Shrinkage (%) 0.164 0.143 0.059 0.063)** 0.068 0.068**
Pause (%) 0.671 0.176 0.884 0.097** 0.865 0.109**
Growth velocity (m/s) 0.257 0.128 0.352 0.210 ns 0.377 0.559 ns
Shrink velocity (m/s) 0.272 0.120 0.349 0.244** 0.419 0.326*
Catastrophe frequency (s1) 0.171 0.104 0.091 0.074** 0.103 0.106**
Rescue frequency (s1) 0.187 0.098 0.087 0.079** 0.099 0.089**
TUBB3-GFP MTs were imaged at 3 s intervals in HeLa cells expressing HSPB1WT , HSPB1R127W , and HSPB1S135F.
Individual TUBB3-GFPMTswere trackedmanually from at least 10 different cells in seven independentmovies. The
MT life histories are represented as the percentage of time spent in growth, shrinkage, or pause. Catastrophe
frequency is given as the frequency that MTs transitioned from growth (or pause) to shrinkage. Rescue frequency
corresponds to the frequency at whichMTs transitioned from shrinkage (or pause) to growth. Data are presented as
average SD. *p 0.05; **p 0.01. ns, Nonsignificant.
Table 2. Hyperactive HSPB1mutants do not affect microtubule polymerization
speed
HSPB1WT
(n 21 cells)
HSPB1R127W
(n 23 cells)
HSPB1S135F
(n 33 cells)
Comet velocity (m/s) 1.415 0.145 1.424 0.221 (ns) 1.438 0.214 (ns)
Distance traveled (m) 18.087 2.154 17.061 2.649 (ns) 17.604 2.629 (ns)
The EB1-GFP comets were imaged at 2 s intervals from HeLa cells expressing HSPB1WT , HSPB1R127W , and
HSPB1S135F. TheEB1-GFP cometswere trackedautomaticallywith the ImageJParticle Tracker plugin fromat least 10
independent movies. Data is presented as average SD. ns, Nonsignificant.
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the reorganization of MTs and cell polarization (Vinogradova et
al., 2009), and addition ofMT stabilizing agents or knockdown of
MTdynamics regulators has previously been shown to reduce cell
migration (Grigoriev et al., 1999; Nakano et al., 2010). Confirm-
ing our previous results, a significant reduction in cell migration
was detected only in cells expressing the hyperactive HSPB1 mu-
tants (R127W and S135F), while cells expressing a CMT-causing
HSPB1mutation without enhanced tubulin binding (T151I) dis-
played a migration speed similar to cells expressing HSPB1WT
(Fig. 3D).
Microtubule stabilization is commonly accompanied by the
acetylation of a lysine residue (Lys40) in -tubulin. Chemical
inhibition of the tubulin deacetylaseHDAC6or treatment of cells
with MT stabilizers was shown to increase tubulin acetylation
(Matsuyama et al., 2002). Conversely, knockout of the tubulin
acetyltransferaseMEC-17was shown to destabilizeMT (Akella et
al., 2010). Based on these data, we decided to check the tubulin
acetylation levels of cells stably expressing different HSPB1 iso-
forms by Western blot. As shown in Figure 3E, the expression of
theMT-stabilizing HSPB1mutations did not change the acetyla-
tion pattern of tubulin. These results were confirmed in different
cell types (data not shown). Together, our results show that hy-
peractive HSPB1 mutants are able to stabilize the MT network,
however, without any increase in tubulin acetylation.
CMT neuropathy causing HSPB1mutants disturb
microtubule dynamics
To examine the effects of the hyperactive HSPB1 mutants on
individual MTs, we used live cell imaging on HeLa cells stably
expressing HSPB1 and transiently transfected with either a GFP-
fused neuron-specific -tubulin isoform (TUBB3-GFP) or GFP-
fused end-binding protein 1 (EB1-GFP). The data for the MT
dynamics extracted from the live cell movies are summarized in
Table 1. In cells expressing the hyperactive HSPB1mutants, MTs
spent significantly less time in the shrinking or growth phase and
more time in the stationary phase compared with the MTs from
HSPB1WT-expressing cells. Accordingly, MTs from cells express-
ing hyperactive HSPB1mutants also displayed lower catastrophe
and rescue frequencies. No differences in growth speed of MTs
were detected, which was confirmed by EB1 tracking (Table 2).
These results are in accordance with what has been previously
Figure4. MutantHSPB1stabilizedmicrotubulesdepolymerizelessoften,butoncetheydo,athigherspeeds.A,Time-lapsemicroscopyfromcellsexpressingHSPB1WTorHSPB1S135FandTUBB3-GFP.Reddots
represent current position ofMT tips,while yellowdots represent the position of theMT tips in the previous frame.MTs in cells expressingHSPB1S135F aremore paused (shownhere as the yellow and red dots
overlappingonthesameposition),butonce theydepolymerize, theyshowafasterdepolymerizationspeedthanMTfromcells expressingHSPB1WT.Scalebar,2m.B, Graphical representationof life storiesof
MTs from cells expressing HSPB1WT andmutants. Note that, in general, MTs inmutant HSPB1-expressing cells move less (are more often on the horizontal axis representing the paused condition) and that,
especially for the depolymerization phase, peaks—representing speed—arehigher formutants. Graph shows the concatenated life story of sevenMTs for each genotype.
Figure 5. Hyperactive HSPB1 mutants stabilize microtubules in vitro. A, MT in vitro polym-
erization assay. Ten micromolar tubulin was polymerized alone or in the presence of 5 M
recombinant HSPB1WT or HSPB1S135F mutant. MT polymerization was measured as increasing
DAPI fluorescence over time (see Experimental procedure section for details). B, Dissociation
constants (KD) of HSPB1WT andHSPB1S135F to tubulin using surface plasmon resonance. Sensor-
gramdatawere fitted using a steady-state bindingmodel, and saturation titration experiments
were for the calculation of KD. AU, Arbitrary units.
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described for other MAPs (Moores et al.,
2006; Faller and Brown, 2009) and suggest
that HSPB1 mutants stabilize microtu-
bules in a similar manner.
Interestingly, MTs from cells express-
ing the hyperactive HSPB1 mutants
showed faster depolymerization speeds
compared with HSPB1WT-expressing
cells. A closer analysis of the tracking data
revealed that a significant fraction of the
MTs from cells expressing the hyperactive
HSPB1 mutants displayed very high de-
polymerization speeds when compared
with cells expressing HSPB1WT (we de-
fined “very high” as a depolymerization
speed higher than the fastest depolymer-
ization speed measured in the HSPB1WT-
expressing cells (0.56 m/s; HSPB1R127W
 12 of 82 MTs analyzed; HSPB1S135F 
21 of 84MTs analyzed) (Fig. 4A,B). These
observations suggest that the hyperactive
HSPB1mutants do not stabilize MTs per-
manently, but rather stabilize them in an
aberrant and transient way by continu-
ously counteracting depolymerization up
to a certain threshold, at which point the
depolymerizing forces are greater than the
stabilization capacity of mutant HSPB1,
causing the MTs to depolymerize very
rapidly. We believe that this also explains
why the increased stabilization is not re-
flected by an increased acetylation.
CMT causing HSPB1mutants are able
to stabilize microtubules in vitro by
direct interaction
The data presented above show that in-
creased binding of HSPB1 mutants stabilizes the MT network in
cells. To test whether this effect is directly caused byHSPB1 bind-
ing or is mediated by other cell signals, we performed an in vitro
MT polymerization assay using recombinant HSPB1WT or
HSPB1S135F protein. In accordance with a stabilization effect
by direct interaction, the presence of HSPB1S135F mutant in the
polymerization reaction strongly facilitated tubulin polymer-
ization when compared with the reactions containing tubulin
alone or tubulin with HSPB1WT (Fig. 5A).
To further investigate the differences in tubulin binding be-
tween HSPB1WT and HSPB1S135F, we measured the binding af-
finities of these proteins (KD) for tubulin by SPR. In line with our
expectations, HSPB1S135F showed a threefold higher affinity for
tubulin than HSPB1WT (KD: HSPB1S135F, 79 nM; HSPB1WT, 343
nM) (Fig. 5B). The stabilization effect by direct binding shown by
the hyperactive HSPB1 mutants further strengthens the hypoth-
esis that these mutants operate in a MAP-like manner.
Mutant HSPB1 stabilizes microtubules in peripheral neurons
fromHSPB1S135F transgenic mice
To check whether the MT-stabilizing effects seen on cells are
relevant in vivo, we used a CMT2F mouse model that selectively
expresses HSPB1S135F in postnatal neurons. These mice present a
phenotype that recapitulates the symptoms seen in patients and
have been described in detail previously (d’Ydewalle et al., 2011).
We first investigated the differential interaction with tubulin by
immunoprecipitating HSPB1 from sciatic nerves from
3-month-old (presymptomatic) mice expressing either
HSPB1WT orHSPB1S135F isoforms. Corroborating our data using
cell lines, HSPB1S135F was found to interact more strongly with
tubulin than does HSPB1WT (Fig. 6A). Furthermore, the effect of
this enhanced interaction on MT stability was confirmed in cul-
tured primary DRG neurons by measuring the extent of the neu-
ritic MT network during and after MT depolymerization
treatment using nocodazole. In contrast to neurons isolated from
HSPB1WT mice that suffered a drastic reduction in neuritic MT
extent during the depolymerization treatment, neurons isolated
from the HSPB1S135F mice displayed only a limited reduction in
their neuritic MT extent (Fig. 6B,C). In the repolymerization
phase, the MT network from HSPB1WT mice neurons showed a
fast recovery to the initial length, while the MT network from
HSPB1S135F mice neurons showed little recovery. These results
confirm that also in peripheral neurons, HSPB1S135F leads to
enhanced stability of theMT network, which might underlie dis-
ease formation in HSPB1S135F-expressing mice and possibly also
in patients.
Discussion
The small heat shock protein HSPB1 is a multifunctional molec-
ular chaperone that participates in a plethora of cellular processes
(Huot et al., 1996; Charette et al., 2000; Cuesta et al., 2000; Paul et
al., 2002). Despite its multifunctionality and ubiquitous expres-
Figure 6. The microtubule-stabilizing property of mutant HSPB1 is confirmed in HSPB1S135F transgenic mice. A, Immunopre-
cipitation of HSPB1 from sciatic nerves of mice expressing HA-tagged HSPB1WT, HSPB1S135F, and nontransgenic (Ntg) mice con-
firmed the differential interaction of HSPB1S135F to tubulin in vivo. B, MT stability measurement on DRG neurons from transgenic
mice.MT stabilitywas evaluatedas the extent of theMTnetworkwithin theDRGneurites fromtransgenicmiceduring (N) andafter
(R) nocodazole treatment (n 40 neurites per time point). Data points for HSPB1S135F are statistically different from HSPB1WT at
all time points, except for those at the start of the treatment (p 0.01). Neuritic MT network extent was normalized to the initial
size before treatment (N0). Data are presented as mean SEM. C, Representative pictures of DRG neurons from transgenic mice
used at measurements shown in B. Neurons are stained for-tubulin. Scale bar, 200M.
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sion, we found that mutations in HSPB1 affect specifically the
peripheral nervous system by causing CMT2F and distal HMN
(Evgrafov et al., 2004). In later work, we discovered that a subset
of HSPB1 mutations are hyperactive and display increased affin-
ity to their client proteins (Almeida-Souza et al., 2010). Here, we
show that an enhanced binding of the CMT-causing HSPB1mu-
tants to tubulin and microtubules causes the molecule to func-
tion in aMAP-likemanner, leading to a reduction inmicrotubule
dynamics. This MT stabilization effect was shown in cells in vitro
and, more importantly, in DRG neurons isolated from a CMT2F
mouse model.
Disturbances in MT dynamics are a well established cause for
neurodegeneration. Similar to our results, mutations in theGTP-
ase dynamin 2 causing dominant intermediate CMT disease,
were shown to decorate MTs and lead to MT stabilization
(Tanabe and Takei, 2009). Recently, mutations in the neuron-
specific tubulin III gene (TUBB3) were associated with type 3
congenital fibrosis of the extraocular muscles and led equally to
MT stabilization. Interestingly, some of these patients presented
with a peripheral neuropathy and were initially diagnosed as
CMT patients (Tischfield et al., 2010). Mutations in the MT-
severing protein spastin (SPG4) constitute the most common
cause of hereditary spastic paraplegia (Depienne et al., 2007).
Disease causingmutations in spastin were described to disturb its
MT severing capacity by impairment of its ATPase activity (Evans
et al., 2005). Microtubule dynamics defects were also linked to
neurodegeneration in Alzheimer’s disease (Bunker et al., 2006)
and Parkinson’s disease (Gillardon, 2009; Cartelli et al., 2010).
In addition to genetic mutations leading to disturbances in
MT dynamics, acquired peripheral neuropathies also are
known to be linked to a misregulation of the MT network.
Chemotherapy-induced peripheral neuropathy is a very com-
mon and a major dose-limiting side effect of many chemothera-
peutic drugs for cancer treatment (Lee and Swain, 2006; Wolf et
al., 2008). Among the commonly used chemotherapeutic drugs,
vinca alkaloids and taxol derivatives are, respectively, potentMT-
depolymerizing and MT-stabilizing agents (Jordan et al., 1985;
Yvon et al., 1999), and are believed to damage peripheral neurons
by disturbing MT dynamics in axons (Meininger et al., 1990;
Swain andArezzo, 2008; Yang et al., 2009). This shows that a tight
balance of MT dynamics seems especially important in the large
axons of peripheral neurons.
In contrast to what is commonly described in the literature
(Matsuyama et al., 2002; Tanabe and Takei, 2009), the MT stabi-
lization caused by hyperactive HSPB1 mutants was shown to
occur independently of any increase in MT acetylation. We be-
lieve that this difference can be explained by the following two
facts: (1) the MT stabilization is not static, as shown by the oc-
currence of high-speed depolymerization events after long pause
periods in mutant-expressing cells (Fig. 4); and (2) the MT sta-
bilization effects caused by the mutants are not very pronounced
(Fig. 3) and, as such, are in accordance with the mild, late-onset
phenotype of this type of CMT disease.
Disturbances inMT dynamics are not by themselves the cause
of neurodegeneration. Actually, these disturbances impair effi-
cient transport of proteins, vesicles, and organelles along the cell.
The highly polarized morphology of neurons makes them espe-
cially vulnerable to transport problems (Perlson et al., 2010).
Looking from a broader perspective and taking axonal transport
defects as a cause of length-dependent neurodegeneration, we
can place MT dynamics-related disorders into a much larger
group of diseases that encompass mutations in other players in-
volved in intracellular transport, such as molecular motors (Puls
et al., 2003) and vesicle recruitment factors (Verhoeven et al.,
2003). The assignment of some HSPB1 mutations into the large
group of neurodegenerative diseases caused by axonal transport
defects represents an important step toward the development of
therapies, as drugs designed to improve axonal transport may
have beneficial effects for several diseases.
In amousemodel forCMT2F,we could confirm the enhanced
interaction of mutant HSPB1 to tubulin and the concomitant
increased stability of the microtubule network. This transgenic
mouse line expresses HSPB1S135F postnatally in neurons and re-
capitulates all features of CMT2F (d’Ydewalle et al., 2011). Pres-
ymptomatically, at 3 months of age, the microtubule network in
peripheral neurons isolated from thesemice showed an enhanced
stability, as reflected by an increased resistance to nocodazole-
induced depolymerization. Interestingly, d’Ydewalle et al. (2011)
observed a clear reduction in acetylation of microtubules, which
is indicative of a lower stability of the microtubule network. In
addition, they found that treatment with an HDAC6 inhibitor
could rescue the disease phenotype. However, these experiments
were performed after disease onset (8 months of age) when ax-
onal loss became clearly apparent. The timing of these observa-
tions therefore suggests that the CMT2F symptoms might be
triggered by the transition from an overstable MT network
caused by the enhanced binding ofmutant HSPB1 to tubulin to a
destabilized MT network mediated by HDAC6 recruitment to
microtubules.
At present, mutations in 10 different HSPB1 residues are
known to cause CMT neuropathy (Houlden et al., 2008; Ikeda et
al., 2009). We tested the five different mutations originally de-
scribed by Evgrafov et al. (2004) and found that three of these
mutations displayed anMT stabilization effect. Interestingly, two
of the other mutated residues (R140 and K141), which we have
not tested, are also present in the HSPB1 dimer interface and
potentially have the same properties as our hyperactive mutants.
On the other hand, the mutations (T151I and P182L) did not
show any differential binding to tubulin or MTs. Therefore, a
complete understanding of all cellular processes explaining the
neuron-specific pathogenesis for all HSPB1 mutations remains
elusive.
In conclusion, our work shows that hyperactive CMT causing
HSPB1 mutations bind excessively to MTs, which leads to their
stabilization. Based on ourmouse data, we believe that this could
be a potential pathomechanism for CMT2F, further underscor-
ing the pivotal role of a fine-tuned regulation of the microtubule
cytoskeleton in neuronal homeostasis.
References
Akella JS, Wloga D, Kim J, Starostina NG, Lyons-Abbott S, Morrissette NS,
Dougan ST, Kipreos ET, Gaertig J (2010) MEC-17 is an alpha-tubulin
acetyltransferase. Nature 467:218–222.
Almeida-Souza L, Goethals S, deWinter V, Dierick I, Gallardo R, VanDurme
J, Irobi J, Gettemans J, Rousseau F, Schymkowitz J, Timmerman V, Jans-
sens S (2010) Increasedmonomerization ofmutantHSPB1 leads to pro-
tein hyperactivity in Charcot-Marie-Tooth neuropathy. J Biol Chem
285:12778–12786.
Baas PW, Karabay A, Qiang L (2005) Microtubules cut and run. Trends Cell
Biol 15:518–524.
Barisic N, Claeys KG, Sirotkovic´-Skerlev M, Löfgren A, Nelis E, De Jonghe P,
Timmerman V (2008) Charcot-Marie-Tooth disease: a clinico-genetic
confrontation. Ann Hum Genet 72:416–441.
Barron DM, Chatterjee SK, Ravindra R, Roof R, Baloglu E, Kingston DG,
Bane S (2003) A fluorescence-based high-throughput assay for antimi-
crotubule drugs. Anal Biochem 315:49–56.
Bhattacharya R, Cabral F (2004) A ubiquitous beta-tubulin disrupts micro-
tubule assembly and inhibits cell proliferation. Mol Biol Cell
15:3123–3131.
Almeida-Souza et al. • HSPB1 Mutations Link Microtubule Dynamics to CMT J. Neurosci., October 26, 2011 • 31(43):15320–15328 • 15327
Bolte S, Cordelie`res FP (2006) A guided tour into subcellular colocalization
analysis in light microscopy. J Microsc 224:213–232.
Bunker JM, Kamath K,Wilson L, JordanMA, Feinstein SC (2006) FTDP-17
mutations compromise the ability of tau to regulate microtubule dynam-
ics in cells. J Biol Chem 281:11856–11863.
Cartelli D, Ronchi C, Maggioni MG, Rodighiero S, Giavini E, Cappelletti G
(2010) Microtubule dysfunction precedes transport impairment andmi-
tochondria damage inMPP-induced neurodegeneration. J Neurochem
115:247–258.
Charette SJ, Lavoie JN, Lambert H, Landry J (2000) Inhibition of Daxx-
mediated apoptosis by heat shock protein 27.MolCell Biol 20:7602–7612.
Cuesta R, Laroia G, Schneider RJ (2000) Chaperone hsp27 inhibits transla-
tion during heat shock by binding eIF4G and facilitating dissociation of
cap-initiation complexes. Genes Dev 14:1460–1470.
Depienne C, Stevanin G, Brice A, Durr A (2007) Hereditary spastic paraple-
gias: an update. Curr Opin Neurol 20:674–680.
d’Ydewalle C, Krishnan J, Chiheb DM, Van Damme P, Irobi J, Kozikowski AP,
Vanden Berghe P, TimmermanV, RobberechtW, VanDen Bosch L (2011)
HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-
induced Charcot-Marie-Tooth disease. NatMed 17:968–974.
Evans KJ, Gomes ER, Reisenweber SM, Gundersen GG, Lauring BP (2005)
Linking axonal degeneration to microtubule remodeling by Spastin-
mediated microtubule severing. J Cell Biol 168:599–606.
Evgrafov OV, Mersiyanova I, Irobi J, Van Den Bosch L, Dierick I, Leung CL,
Schagina O, Verpoorten N, Van Impe K, Fedotov V, Dadali E, Auer-
Grumbach M, Windpassinger C, Wagner K, Mitrovic Z, Hilton-Jones D,
Talbot K, Martin JJ, Vasserman N, Tverskaya S, Polyakov A, Liem RK,
Gettemans J, Robberecht W, De Jonghe P, Timmerman V (2004) Mu-
tant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth dis-
ease and distal hereditary motor neuropathy. Nat Genet 36:602–606.
Faller EM, Brown DL (2009) Modulation of microtubule dynamics by the
microtubule-associated protein 1a. J Neurosci Res 87:1080–1089.
Gillardon F (2009) Leucine-rich repeat kinase 2 phosphorylates brain tubulin-
beta isoforms andmodulates microtubule stability—a point of convergence
in parkinsonian neurodegeneration? J Neurochem 110:1514–1522.
Grigoriev IS, Chernobelskaya AA, Vorobjev IA (1999) Nocodazole, vinblas-
tine and taxol at low concentrations affect fibroblast locomotion and
saltatory movements of organelles. Membr Cell Biol 13:23–48.
Halpain S, Dehmelt L (2006) The MAPI family of microtubule-associated
proteins. Genome Biol 7:224.
Haslbeck M, Franzmann T, Weinfurtner D, Buchner J (2005) Some like it
hot: the structure and function of small heat-shock proteins. Nat Struct
Mol Biol 12:842–846.
Houlden H, Laura M, Wavrant-De Vrie`ze F, Blake J, Wood N, Reilly MM
(2008) Mutations in the HSP27 (HSPB1) gene cause dominant, reces-
sive, and sporadic distal HMN/CMT type 2. Neurology 71:1660–1668.
Huot J, Houle F, Spitz DR, Landry J (1996) HSP27 phosphorylation-
mediated resistance against actin fragmentation and cell death induced by
oxidative stress. Cancer Res 56:273–279.
Ikeda Y, Abe A, Ishida C, Takahashi K, Hayasaka K, Yamada M (2009) A
clinical phenotype of distal hereditary motor neuronopathy type II with a
novel HSPB1 mutation. J Neurol Sci 277:9–12.
Jordan MA, Himes RH, Wilson L (1985) Comparison of the effects of vin-
blastine, vincristine, vindesine, and vinepidine on microtubule dynamics
and cell proliferation in vitro. Cancer Res 45:2741–2747.
Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubule-
stabilizing agents. J Clin Oncol 24:1633–1642.
Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin-
Berny D, Osada H, Komatsu Y, Nishino N, Khochbin S, Horinouchi S,
Yoshida M (2002) In vivo destabilization of dynamic microtubules by
HDAC6-mediated deacetylation. EMBO J 21:6820–6831.
Meininger V, Binet S, Chaineau E, Fellous A (1990) In situ response to vinka
alkaloids by microtubules in cultured post-implanted mouse embryos.
Biol Cell 68:21–29.
Melki R, CarlierMF, PantaloniD, Timasheff SN (1989) Cold depolymeriza-
tion of microtubules to double rings: geometric stabilization of assem-
blies. Biochemistry 28:9143–9152.
Moores CA, PerderisetM, Kappeler C, Kain S, DrummondD, Perkins SJ, Chelly
J, Cross R, Houdusse A, Francis F (2006) Distinct roles of doublecortin
modulating the microtubule cytoskeleton. EMBO J 25:4448–4457.
Nakano A, Kato H, Watanabe T, Min KD, Yamazaki S, Asano Y, Seguchi O,
Higo S, Shintani Y, Asanuma H, Asakura M, Minamino T, Kaibuchi K,
Mochizuki N, Kitakaze M, Takashima S (2010) AMPK controls the
speed of microtubule polymerization and directional cell migration
through CLIP-170 phosphorylation. Nat Cell Biol 12:583–590.
Paul C,Manero F, Gonin S, Kretz-RemyC,Virot S, ArrigoAP (2002) Hsp27 as
a negative regulator of cytochrome C release. Mol Cell Biol 22:816–834.
Perlson E, Maday S, Fu MM, Moughamian AJ, Holzbaur EL (2010) Ret-
rograde axonal transport: pathways to cell death? Trends Neurosci
33:335–344.
Puls I, JonnakutyC, LaMonteBH,Holzbaur EL, TokitoM,MannE, FloeterMK,
Bidus K, Drayna D, Oh SJ, Brown RH Jr, Ludlow CL, Fischbeck KH (2003)
Mutant dynactin inmotor neuron disease. Nat Genet 33:455–456.
Salmon P, Trono D (2006) Production and titration of lentiviral vectors.
Curr Protoc Neurosci Chapter 4: Unit 4.21.
Sun Y, MacRae TH (2005) The small heat shock proteins and their role in
human disease. Febs J 272:2613–2627.
Swain SM, Arezzo JC (2008) Neuropathy associated with microtubule in-
hibitors: diagnosis, incidence, and management. Clin Adv Hematol On-
col 6:455–467.
Tanabe K, Takei K (2009) Dynamic instability of microtubules requires dy-
namin 2 and is impaired in a Charcot-Marie-Tooth mutant. J Cell Biol
185:939–948.
TischfieldMA, Baris HN,Wu C, Rudolph G, VanMaldergem L, HeW, Chan
WM, Andrews C, Demer JL, Robertson RL, Mackey DA, Ruddle JB, Bird
TD, Gottlob I, Pieh C, Traboulsi EI, Pomeroy SL, Hunter DG, Soul JS,
Newlin A, et al. (2010) Human TUBB3 mutations perturb microtubule
dynamics, kinesin interactions, and axon guidance. Cell 140:74–87.
Tsai A, Carstens RP (2006) An optimized protocol for protein purification
in cultured mammalian cells using a tandem affinity purification ap-
proach. Nat Protoc 1:2820–2827.
Verhoeven K, De Jonghe P, Coen K, Verpoorten N, Auer-Grumbach M,
Kwon JM, FitzPatrick D, Schmedding E, De Vriendt E, Jacobs A, Van
Gerwen, V, Wagner K, Hartung HP, Timmerman V (2003) Mutations
in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-
Tooth type 2B neuropathy. Am J Hum Genet 72:722–727.
Vinogradova T, Miller PM, Kaverina I (2009) Microtubule network asym-
metry in motile cells role of Golgi-derived array. Cell Cycle 8:2168–2174.
Wolf S, BartonD,Kottschade L,GrotheyA, Loprinzi C (2008) Chemotherapy-
induced peripheral neuropathy: prevention and treatment strategies. Eur J
Cancer 44:1507–1515.
Yang IH, Siddique R, Hosmane S, Thakor N, Ho¨ke A (2009) Compartmen-
talized microfluidic culture platform to study mechanism of paclitaxel-
induced axonal degeneration. Exp Neurol 218:124–128.
Yvon AM, Wadsworth P, Jordan MA (1999) Taxol suppresses dynamics of
individual microtubules in living human tumor cells. Mol Biol Cell 10:
947–959.
15328 • J. Neurosci., October 26, 2011 • 31(43):15320–15328 Almeida-Souza et al. • HSPB1 Mutations Link Microtubule Dynamics to CMT
